Price$65.69-0.44 (-0.67%)
01:30 PM07:45 PM
News · 26 weeks69-33%
2025-10-262026-04-19
Mix5090d
- Insider25(50%)
- SEC Filings14(28%)
- Other6(12%)
- Earnings4(8%)
- Analyst1(2%)
Latest news
25 items- SECBoston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRBoston Scientific announces results for first quarter 2026MARLBOROUGH, Mass., April 22, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.341 billion or $0.90 per share (EPS), compared to $674 million or $0.45 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.75 a year ago. "Our global
- SECSEC Form EFFECT filed by Boston Scientific CorporationEFFECT - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- SECSEC Form 424B3 filed by Boston Scientific Corporation424B3 - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- ANALYSTBoston Scientific downgraded by Raymond James with a new price targetRaymond James downgraded Boston Scientific from Strong Buy to Outperform and set a new price target of $88.00
- PRBoston Scientific announces conference call discussing first quarter 2026 resultsMARLBOROUGH, Mass., March 30, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2026, on Wednesday, April 22, 2026, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Jon Monson, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 22 prior to the conference call. A live webcast and replay for the ev
- SECAmendment: SEC Form S-4/A filed by Boston Scientific CorporationS-4/A - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- SECBoston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRCHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpointsData highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation Late-breaking findings presented at ACC.26 and simultaneously published in The New England Journal of MedicineMARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first
- PRHI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolismGlobal randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation aloneLate breaking findings presented at ACC.26 and simultaneously published in The New England Journal of MedicineMARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive data from the HI-PEITHO global randomized clinical trial evaluating the use of the EKOS™ Endovascular System in patients with intermediate-risk pulmonary embolism (PE). The study met the composite primary endpoint, with data demonstrating tha
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific CorporationSCHEDULE 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
- SECSEC Form DEFA14A filed by Boston Scientific CorporationDEFA14A - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- SECSEC Form DEF 14A filed by Boston Scientific CorporationDEF 14A - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- SECSEC Form PRE 14A filed by Boston Scientific CorporationPRE 14A - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRBoston Scientific to host investor event at the 75th Annual Scientific Session of the American College of CardiologyMARLBOROUGH, Mass., March 6, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host an investor event and live webcast on Saturday, March 28, 2026, at 6:30 p.m. ET / 5:30 p.m. CT to discuss key clinical data presented earlier that day at the 75th Annual Scientific Session of the American College of Cardiology. The event will be hosted by Dr. Kenneth Stein, senior vice president and global chief medical officer, Dr. Brad Sutton, chief medical officer, AF solutions and Dr. Michael R. Jaff, vice president and chief medical officer, vascular therapies. The live web
- INSIDERSEC Form 4 filed by Director Pegus Cheryl4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Weber Christophe Pierre was granted 879 shares (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith Cathy R4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Morano Susan E was granted 24 shares, increasing direct ownership by 0.36% to 6,663 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERSVP, Global Controller and CAO Woodworth Emily converted options into 838 shares and covered exercise/tax liability with 372 shares, increasing direct ownership by 19% to 2,859 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERSEC Form 4 filed by EVP& Grp Pres, MedSurg & APAC Butcher Arthur C4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECSEC Form S-4 filed by Boston Scientific CorporationS-4 - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- SECBoston Scientific Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRPenumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial ResultsALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights:Revenue of $385.4 million for the fourth quarter of 2025, an increase of 22.1% or 20.9% in constant currency1, compared to the fourth quarter of 2024.Revenue of $1,403.7 million for the full year 2025, an increase of 17.5% or 16.9% in constant currency1, compared to the full year 2024.U.S. Thrombectomy revenue of $203.1 million for the fourth quarter
- INSIDERSEC Form 3 filed by new insider Weber Christophe Pierre3 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)